Analyst Price Targets — CATX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 17, 2026 12:35 pm | Greg Renza | Truist Financial | $12.00 | $5.09 | StreetInsider | Truist Reiterates Buy Rating on Perspective Therapeutics Inc (CATX) |
| February 19, 2026 10:11 am | Biren Amin | Piper Sandler | $16.00 | $5.03 | TheFly | Perspective Therapeutics initiated with an Overweight at Piper Sandler |
| January 30, 2026 11:08 am | — | H.C. Wainwright | $12.00 | $4.26 | TheFly | Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright |
| November 21, 2025 12:26 am | David Lai | UBS | $7.00 | $2.12 | TheFly | Perspective Therapeutics price target lowered to $7 from $18 at UBS |
| October 10, 2025 10:59 am | Jeet Mukherjee | BTIG | $14.00 | $4.20 | TheFly | Perspective Therapeutics initiated with a Buy at BTIG |
| October 24, 2024 3:50 am | David Dai | UBS | $20.00 | $11.69 | StreetInsider | UBS Starts Perspective Therapeutics Inc (CATX) at Buy |
| October 14, 2024 6:07 am | Jeff Jones | Oppenheimer | $22.00 | $12.66 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX) |
| September 25, 2024 6:10 am | Nicole Germino | Truist Financial | $21.00 | $12.28 | StreetInsider | Truist Securities Starts Perspective Therapeutics Inc (CATX) at Buy |
| July 25, 2024 6:11 am | Alec Stranahan | Bank of America Securities | $24.00 | $12.82 | TheFly | Perspective Therapeutics initiated with a Buy at BofA |
| June 18, 2024 7:26 am | Jeff Jones | Oppenheimer | $19.00 | $11.93 | StreetInsider | Perspective Therapeutics Inc (CATX) PT Raised to $19 at Oppenheimer |
Latest News for CATX
SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of…
Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contributions to more than 30 oncology programs Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contributions to more than 30 oncology programs
Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug [212Pb]VMT-a-NET, broadening a clinical trial that previously focused only on a different cancer type known as neuroendocrine tumors. The new arm of the Phase 1/2a study, called LEMONaDE, aims to assess how safe the treatment is and whether it shows early signs of…
Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug...
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CATX.
U.S. House Trading
No House trades found for CATX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.